
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LX-96
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Symbiosis Pharmaceutical Services
Deal Size : $10.0 million
Deal Type : Financing
Paradox Gets $10M from SymBiosis to Advance Protein Misfolding Disease Therapies
Details : The financing will be used to advance Paradox’s therapeutic pipeline, which includes LX-96, a monoclonal antibody designed for the treatment of late-stage immunoglobulin light chain (AL) amyloidosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : LX-96
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Symbiosis Pharmaceutical Services
Deal Size : $10.0 million
Deal Type : Financing
